Max Lataillade, MPH, DO
About
Appointments
Infectious Diseases
Assistant Clinical ProfessorPrimary
Other Departments & Organizations
Education & Training
- DO
- University of Medicine and Dentistry of New Jersey (2001)
- MPH
- George Washington School of Medicine (1995)
- BS
- Howard University (1992)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Max Lataillade's published research.
Publications Timeline
A big-picture view of Max Lataillade's research output by year.
Samit Joshi, DO, MPH
4Publications
Publications
2024
Augmentation des lymphocytes T CD4+ et réduction générale des biomarqueurs inflammatoires indépendamment du taux de lymphocytes T CD4+ à l'inclusion pendant 240 semaines de traitement par fostemsavir (FTR) + traitement de fond optimisé (TFO) dans l'étude BRIGHTE
Pialoux G, Dyson A, Castillo-Mancilla J, Du F, Li B, Lataillade M, Tenorio A, Clark A, Prakash M, Neau D. Augmentation des lymphocytes T CD4+ et réduction générale des biomarqueurs inflammatoires indépendamment du taux de lymphocytes T CD4+ à l'inclusion pendant 240 semaines de traitement par fostemsavir (FTR) + traitement de fond optimisé (TFO) dans l'étude BRIGHTE. Médecine Et Maladies Infectieuses Formation 2024, 3: s142. DOI: 10.1016/j.mmifmc.2024.04.388.Peer-Reviewed Original ResearchModèles multivariés étendus pour identifier les facteurs prédictifs de la réponse virologique au fostemsavir dans l'étude BRIGHTE
Marcelin A, Li B, Du F, Krystal M, Clark A, Lataillade M, Tenorio A, Castillo-Mancilla J, Gartland M, Wang X. Modèles multivariés étendus pour identifier les facteurs prédictifs de la réponse virologique au fostemsavir dans l'étude BRIGHTE. Médecine Et Maladies Infectieuses Formation 2024, 3: s141-s142. DOI: 10.1016/j.mmifmc.2024.04.387.Peer-Reviewed Original Research
2023
365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment
Dyson A, Aberg J, Molina J, Cassetti I, Kozal M, Treviño-Pérez S, Latiff G, Lalezari J, Pialoux G, Li B, Prakash M, Clark A, Tenorio A, Pierce A, Lataillade M. 365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment. Open Forum Infectious Diseases 2023, 10: ofad500.435. PMCID: PMC10676856, DOI: 10.1093/ofid/ofad500.435.Peer-Reviewed Original ResearchConceptsMultidrug-resistant HIV-1T-cell countsVirologic response ratesCells/mm3Randomized cohortHIV-1Response rateBL CD4Viral loadDisease characteristicsTreatment optionsAdvanced HIV-1Current ARV regimenPlacebo-controlled periodTreatment-experienced peopleT-cell increaseLimited treatment optionsLong-term efficacyOverall response rateLow response rateBackground therapyContinuous CD4Suppressive regimensWeek 96Virologic responseEffects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants
Zhang Y, Bush M, Yazdani P, Zhan J, Wen B, Bainbridge V, Wynne B, Joshi S, Lataillade M. Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants. Pharmacology Research & Perspectives 2023, 11: e01151. PMID: 37961928, PMCID: PMC10644204, DOI: 10.1002/prp2.1151.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsConcentration-QTc analysisHealthy participantsQT intervalNovel HIV-1 maturation inhibitorsPlacebo-adjusted changeHIV-1 treatmentHIV-1 maturation inhibitorsMoxifloxacin doseSupratherapeutic dosePlasma concentrationsRelevant effectsFridericia's formulaTreatment periodCardiac repolarizationHeart rateMaturation inhibitorsCardiac conductionCardiac parametersDay 7QT studyDoseTime pointsGSK3640254ΔΔQTcFPharmacokinetics